---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-016344"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T02:00:44.561182+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MetaVia (MTVA) announces positive Phase 2a top-line results for DA-1241 in MASH patients

## Summary
- DA-1241 100mg achieved statistically significant ALT reduction at weeks 4 and 8 (p=0.0159, p=0.0342), near significant at week 16 (p=0.0506).
- Statistically significant improvements in CAP score (p=0.0308) and HbA1C (p=0.0179) vs placebo at week 16.
- DA-1241 was very well tolerated; no drug-related serious adverse events reported across treatment groups.
- Company plans end-of-Phase 2 meeting with FDA in first half of 2025; full data set awaited.
- DA-1241 100mg + sitagliptin also showed significant FAST score reduction (p=0.0416).

## SEC filing metadata
- accession: 0001558370-24-016344
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024016344/0001558370-24-016344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024016344/mtva-20241218x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-016344
- JSON: https://secwatch.observer/filing/0001558370-24-016344.json
- Plain text: https://secwatch.observer/filing/0001558370-24-016344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.